The study specifically targeted female patients diagnosed with Long-COVID illness, also known as Post-Acute Sequelae of COVID-19 infection (PASC).
After undergoing a 14-week treatment regimen consisting of valacyclovir and celecoxib, these patients experienced significant enhancements in fatigue levels, pain management, symptoms related to autonomic dysfunction, and overall well-being.
These improvements were evident when comparing the results within the treatment group and against a control cohort receiving standard care.
Buoyed by these positive outcomes, Virios Therapeutics intends to schedule a meeting with the Food and Drug Administration (FDA) later this year to explore the possibility of initiating an investigational new drug application for treating Long-COVID symptoms using this combination therapy.